Fresenius Kabi believes “everything is working according to plan” following its recent launch of the first US biosimilar Actemra (tocilizumab), its Tyenne (tocilizumab-aazg) intravenous formulation, and says it has been “working very hard on access,” although the German firm concedes that the financial benefits will be muted for a couple of quarters.
Kabi Awaits Biosimilar Tocilizumab Boost, Upgrades 2024 Guidance
Follows Recent US Launch And Increasing European Roll Out, ‘Very Confident’
Fresenius Kabi enjoyed a good start to 2024, boosted by the recent US launch of its biosimilar tocilizumab product and a key licensing agreement signed with Teva – factors that have allowed the German generics and biosimilars giant to boost its financial guidance for 2024.
More from Strategy
• By
South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
More from Business
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.